Outcome of Board Meeting

("Par Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara -390 007. Gujarat (INDIA). Ph. : +91-265-2991021 / 2991022 DRUGS AND CHEMICALS LIMITED Email: admin@lpardrugs.com CIN No.: L24117GJ1999PLC035512 ----------------------------------------------- www.pardrugs.com PAR/CS/NSE/2026-27 /26 Date: 29/10/2026 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051 Maharashtra Subject: Outcome of the Board Meeting held on Thursday, 29th day of October, 2026 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 Ref.: Symbol-PAR, ISIN: INE04LG01015 Dear Sir/Madam, The meeting of Board of Directors of the Company held on Thursday, 29th day of October, 2026 at 4:00 PM through Video Conferencing ("VC") mode, transacted the following businesses: Item Outcomes 1. After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record the Unaudited Standalone Financial Results of the Company for quarter and half year ended on September 30, 2026 along with Limited Review Report given by CA Mira! Mehta, Partner of Sarupria Somani & Associates, Chartered Account'ants having valid Peer Review Certificate, Statutory Auditor of the Company. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203) to sign the approved financial results with notes. The financial results were duly reviewed by Audit Committee at its meeting. Pursuant to Regulation 33(2)(a) of SEBI {Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting as attached herewith in the annexure. {Limited Review Report with statements of financial are attached as an Annexures) 2. The Board considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter and half year ended on September 30, 2026. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay or as available. Page 1 of2 Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara -390 007. Gujarat (INDIA). Ph.: +91-265-2991021 / 2991022 DRUGS AND CHEMICALS LIMITED Email: admin@)pardrugs.com CIN No.: L24117GJ1999PLC035512 ----------------------------------------------- www.pardrugs.com 3. The Board took note of Investor grievances report for the quarter ended September 30, 2026 and reviewed the SCORES platform of SEBI to solve the investor compliant till date. 4. The Board took note and review the Corporate Governance Report of the Company for the quarter ended September 30, 2026 5. There were no other material items to be discussed and taken for proposal. Further, with reference to our intimation dated 28th September, 2026 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of declaration of the attached financial result for Designated persons, Designated employees and their Immediate relatives. The Board Meeting was commenced at 4:00 PM and concluded at ~ PM. Kindly take on the record and acknowledge the receipt. Yours Faithfully, For PAR DRUGS AND CHEMICALS LIMITED (Sanket B. Trivedi) Company Secretary & Compliance Officer Annexure: 1. Limited Review Report on standalone un-audited Quarterly and half year ended September 30, 2026 2. Standalone Un-Audited Financial Results for the Quarter and half year ended September 30, 2026 with notes 3. Certificate of Correctness of financial Statement Page 2 of2 CA Miral B. Mehta Sarupria Somani & Associates 602, Victoria Corporate, Chartered Accountants Opp. Gulista Ground, Sony Shov Room Lane, Vadodariya Park, Bhavnagar.Gujarat-364001 ... Partner • CA Miral Bipinbhai Mehta Mobile: 9909366366 B.Com, FCA Email : somanibvn@gmail.com Limited Review Report on standalone un-audited Quarterly financial results for the quarter and half year ended 30th September, 2026 of Par Drugs and Chemicals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 The Board of Directors Par Drugs and Chemicals Limited We have reviewed the accompanying statement of unaudited financial results of Par Drugs and Chemicals Limited having its registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara, Gujarat-390007 for the quarter and half year ended 30th September, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies h~s ~~:::::::,..: Branches Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • gar Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter. SARUPRIA SOMANI & ASSOCIATES {Firm Regn No. - 010674() CHARTERED ACCOUNTANTS MIRAL MEHTA {Partner) M.No.145361 Bhavnagar, 29th October, 2026 UDIN - 26145361OKLOOM8149 PAR DRUGS AND CHEMICALS LIMITED (CIN : U4117GJ1999PLC035512) Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India Phone No. +91-265-2991020/2991022, Email: admln@pardrugs.com Website: www.pardrugs.com Standalone Audited Financial Results for the Quarter and Half Year Ended 30th September, 2026 Statement Of Profit & Loss (Rs. In Lakhs) Particulars Quarter Ended Year to Date Year Ended 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Revenue from operations 2,743.19 3,128.05 2,865.89 5,871.24 5,470.53 10,365.56 II Other income 0.08 93.53 48.02 93.62 231.69 400.07 Ill Total Revenue (I + II) 2,743.27 3,221.58 2,913.91 5,964.86 5,702.22 10,765.63 IV Expenses: Cost of materials consumed 1,327.66 1,283.50 1,054.23 2,611.16 2,170.55 4,267.05 Purchases of Stock-in-Trade 0.00 0.00 0.00 0.00 0.00 0.00 Changes in inventories of finished goods, Stock-in- -65.33 90.89 18.13 25.56 35.35 69.09 Trade and work-in-progress Employee benefits expense 148.41 168.92 135.49 317.33 277.45 612.01 Finance costs 1.65 2.14 5.49 3.79 7.12 12.73 Depreciation and amortization expense 94.35 96.42 94.11 190.77 184.45 370.33 Other expenses 882.17 946.70 1,051.44 1,828.88 2,024.49 3,704.26 Total expenses (IV) 2,388.91 2,588.57 2,358.89 4,977.49 4,699.41 9,035.48 V Profit/ [Showing first 8,000 characters — download PDF for full document]